C4A and systemic lupus erythematosus: In the past decade, cell-bound levels of processed complement activation products (CBCAPS), especially erythrocyte-bound C4 (E-C4d), has been proposed to assist in the diagnosis and clinical monitoring of SLE (16, 17).